超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

Endosense  
Endosense于2003年在日內瓦成立，是一家醫療科技公司，致力于改善治療心律失常的導管消融術的功效、安全性和易用性。公司在開發TactiCath*時率先在導管消融術中采用了觸點壓力測量，TactiCath是第一種壓敏消融導管，允許醫生在實施導管消融術時實時、客觀地測量接觸力。Endosense得到Edmond de Rothschild Investment Partners、Neomed、Gimv、VI Partners、Sectoral Asset Management、Ysios Capital Partners及Initiative Capital Romandie等投資公司的投資支持。

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of Contact Force in catheter ablation.

The company’s flagship product is the TactiCath Quartz?, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Already distributed in Europe, Australia and New Zealand, this force-sensing catheter has undergone extensive pre-clinical and clinical validation.

Endosense’s target patient population is sizeable, as the TactiCath Quartz? may be used to treat a range of cardiac rhythm disorders, including atrial fibrillation (AF).The current estimate of the prevalence of atrial fibrillation (AF) in the developed world is approximately 1.5–2% of the general population1 (six million patients in the US alone).

In the past, most AF patients have been treated with pharmaceutical drugs that do not address the underlying cause and have side effects, with invasive ablation surgery as the primary treatment alternative. Now, catheter ablation has become a minimally invasive and safe treatment option for atrial fibrillation.2